Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour By Ogkologos - March 18, 2026 143 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANEUVER study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly... April 17, 2024 Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients... November 21, 2020 Laser-Based Device Detects and Kills Melanoma Cells in the Blood, Study... July 25, 2019 New Generation of Antibody-Drug Conjugates (ADCs) Shows Unprecedented Promise in Early-Stage... October 18, 2025 Load more HOT NEWS A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity... Spending Review 2020 – Steps in the right direction, but opportunities... FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched...
